cyclophilin
peptidylprolyl
cistran
isomeras
ppias
catalys
interconvers
peptid
bond
prolin
residu
sever
cyclophilin
play
pivot
role
life
cycl
number
virus
exist
cyclophilin
inhibitor
deriv
cyclosporin
sanglifehrin
disadvantag
includ
size
potenti
side
effect
unrel
cyclophilin
inhibit
drugdrug
interact
unclear
antivir
spectrum
manufactur
issu
use
fragmentbas
drug
discoveri
approach
use
nucleic
magnet
reson
xray
crystallographi
structurebas
compound
optim
gener
new
famili
nonpeptid
smallmolecul
cyclophilin
inhibitor
potent
vitro
ppias
inhibitori
activ
antivir
activ
hepat
c
viru
human
immunodefici
viru
coronavirus
famili
compound
potenti
broadspectrum
highbarriertoresist
treatment
viral
infect
ver
past
decad
increas
number
virus
caus
unexpect
ill
epidem
among
human
wildlif
livestock
emerg
outbreak
serious
stretch
local
nation
resourc
econom
develop
world
wherea
capac
control
emerg
diseas
remain
limit
poorer
region
mani
origin
number
virusspecif
antivir
agent
develop
commerci
sinc
earli
agent
includ
drug
specif
inhibit
member
herpesvirida
famili
influenza
virus
human
immunodefici
viru
hiv
hepat
b
viru
hbv
recent
hepat
c
viru
hcv
major
medic
impact
howev
develop
cost
specif
antivir
agent
extrem
high
mani
medic
import
viral
infect
requir
efficaci
therapi
thu
urgent
need
new
famili
broadspectrum
antivir
agent
antivir
agent
activ
number
differ
viral
famili
compound
target
mechan
common
differ
famili
virus
cellular
compon
andor
function
involv
life
cycl
cellular
protein
cyclophilin
shown
play
key
role
life
cycl
number
differ
viral
famili
addit
cyclophilin
inhibitor
report
inhibit
replic
differ
virus
vitro
vivo
thu
cyclophilin
repres
attract
target
broadspectrum
antivir
inhibit
cyclophilin
peptidylprolyl
cistran
isomeras
ppias
catalys
interconvers
two
energet
prefer
conform
ci
tran
planar
peptid
bond
preced
intern
prolin
residu
seventeen
human
cyclophilin
identifi
thu
far
among
cyclophilin
cypa
present
cytosol
involv
protein
fold
traffick
immunomodul
cell
signal
extracellular
fraction
cypb
involv
cellcel
commun
inflammatori
signal
cypd
local
matrix
mitochondria
act
key
regul
open
mitochondri
permeabl
transit
pore
mptp
play
major
role
calcium
efflux
mitochondria
cytosol
lead
mitochondri
swell
cell
death
function
remain
cyclophilin
unknown
cyclophilin
share
common
domain
amino
acid
cyclophilinlik
domain
surround
domain
uniqu
member
famili
associ
subcellular
compartment
function
special
cyclophilin
adopt
eightstrand
antiparallel
pbarrel
structur
fig
ppias
catalyt
groov
form
mixtur
hydrophob
aromat
polar
residu
includ
fig
b
exist
deep
pocket
contigu
canon
catalyt
site
call
gatekeep
pocket
reveal
fig
gatekeep
pocket
might
contribut
substratebind
specif
access
determin
gatekeep
residu
surfac
sever
cyclophilin
includ
princip
exclus
cypa
shown
play
pivot
role
life
cycl
number
virus
includ
hiv
hcv
dengu
viru
japanes
enceph
viru
yellow
fever
viru
coronavirus
hbv
cytomegaloviru
influenza
viru
enterovirus
cyclosporin
csa
nonimmunosuppress
macrocycl
analogu
csa
sanglifehrin
sfa
potent
inhibit
cyclophilin
ppias
activ
bind
catalyt
site
fig
shown
vitro
effect
hiv
hcv
hbv
replic
csa
analogu
alisporivir
show
potent
antihcv
activ
vivo
clinic
develop
halt
phase
iii
programm
due
sever
advers
event
unrel
cyclophilin
inhibit
exist
cyclophilin
inhibitor
deriv
csa
sfa
disadvantag
includ
size
result
poor
cell
permeabl
risk
drugdrug
interact
unclear
antivir
spectrum
effect
hcv
reproduc
demonstr
manufactur
issu
rais
synthesi
alisporivir
complic
hemisynthet
pathway
start
csa
includ
step
use
highli
reactiv
danger
compound
potenti
side
effect
unrel
cyclophilin
inhibit
addit
inhibit
cyclophilin
ppias
activ
csa
instanc
shown
inhibit
mitogenactiv
protein
kinas
pathway
affect
transform
growth
level
wherea
csa
nonimmunosuppress
deriv
report
inhibit
abc
transport
exampl
pgp
mrp
bcrp
stimul
antigen
present
enhanc
major
histocompat
complexi
surfac
express
alisporivir
associ
acut
pancreat
case
includ
one
fatal
case
combin
pegyl
interferona
phase
iii
trial
patient
infect
hcv
mechan
unknown
thu
new
famili
cyclophilin
inhibitor
urgent
need
fragmentbas
drug
discoveri
fbdd
base
identif
small
molecul
fragment
subsequ
expand
link
togeth
gener
drug
lead
therapeut
activ
use
fbdd
approach
use
nucleic
magnet
reson
nmr
xray
crystallographi
gener
new
famili
nonpeptid
smallmolecul
cyclophilin
inhibitor
unrel
csa
sfa
potent
vitro
ppias
inhibitori
activ
antivir
activ
sever
famili
virus
respons
frequent
human
infect
fragment
screen
total
fragment
comput
dock
canon
activ
site
gatekeep
pocket
cypd
mean
flexx
programm
fortyfour
fragment
select
base
mode
interact
abil
interact
cypd
studi
mean
nmr
spectroscopi
ten
fragment
hit
lowaffin
dissoci
constant
millimolar
rang
identifi
supplementari
fig
scaffold
prolinemimick
motif
use
select
cerebro
set
deriv
fragment
subsequ
xray
crystallograph
experi
apo
cypd
crystal
soak
fragment
xray
structur
cypd
complex
fragment
obtain
supplementari
fig
show
chemic
structur
bind
fragment
four
fragment
bound
catalyt
site
cypd
wherea
five
fragment
bound
gatekeep
pocket
fragment
bound
two
site
final
four
fragment
nonspecif
multibind
densiti
map
fragment
shown
supplementari
fig
http
figsharecom
abil
fragment
inhibit
cyclophilin
activ
vitro
assess
cellfre
enzym
assay
cypa
cypb
cypd
halfmaxim
inhibitori
concentr
ic
fragment
mm
instanc
fragment
select
link
among
fragment
hit
final
select
compound
subsequ
compound
optim
base
number
criteria
includ
ligand
effici
abil
access
key
region
synthet
tractabl
possibl
link
gener
articl
natur
commun
doi
compound
bind
catalyt
site
gatekeep
pocket
xray
crystallograph
structur
cypd
complex
fragment
solv
resolut
show
fragment
deepli
buri
gatekeep
pocket
hydrophil
region
fig
amino
group
displac
water
molecul
present
pocket
apo
form
cypd
within
gatekeep
pocket
fragment
made
one
direct
hydrogen
bond
two
hydrogen
bond
water
molecul
fig
crystallograph
structur
cypd
complex
fragment
solv
resolut
fig
addit
hydrophob
contact
within
catalyt
site
cypd
fragment
directli
interact
via
hydrogen
bond
fig
link
strategi
superimposit
fragment
known
structur
csa
sfa
two
cyclophilin
inhibitor
suggest
urea
moieti
could
use
linker
two
fragment
one
hydrogen
bond
two
fig
compound
consist
fragment
connect
urea
moieti
thu
gener
fig
compound
inhibit
cypd
activ
ic
mm
tabl
structur
cypd
complex
compound
obtain
resolut
reveal
bind
gatekeep
pocket
catalyt
site
fig
b
compound
maintain
key
interact
fragment
within
respect
pocket
make
one
one
two
addit
hydrogen
bond
respect
fig
bind
mode
compound
cypd
confirm
mean
nmr
experi
cypd
nheteronuclear
singl
quantum
coher
hsqc
spectrum
reveal
signific
chemic
shift
perturb
ligand
bind
residu
locat
near
catalyt
site
gatekeep
pocket
respect
supplementari
fig
crosspeak
disappear
ligand
addit
like
due
intermedi
chemic
exchang
demonstr
residu
part
bind
site
correspond
amid
proton
locat
proxim
ligand
compound
also
potent
inhibit
cypa
cypb
ic
mm
respect
structurebas
lead
optim
compound
structureguid
optim
use
improv
cyclophilin
affin
stabil
compound
ester
function
often
associ
low
biolog
stabil
first
step
replac
ester
function
compound
make
key
hydrogen
bond
without
affect
cyclophilin
inhibitori
potenc
design
compound
lack
ester
function
lost
interact
result
drastic
decreas
cyclophilin
inhibit
ic
mm
case
compound
tabl
complex
pdb
code
side
chain
push
oxygen
atom
sfa
phenylpyrrolidin
moieti
ad
gener
compound
tabl
shown
fig
compound
share
bind
mode
compound
addit
methoxi
phenylpyrrolidin
moieti
displac
side
chain
make
hydrogen
bond
carbonyl
moieti
urea
motif
fig
http
figshar
comarticlesstereoviewsofcocrystalstructuresofcyclophilin
compound
prove
potent
inhibitor
cypa
cypb
cypd
ppias
activ
ic
mm
respect
seri
phenylpyrrolidin
deriv
synthes
includ
compound
tabl
tabl
show
inhibitori
effect
compound
cypa
cypb
cypd
ppias
activ
enzym
assay
compound
anilin
motif
report
potenti
bear
toxic
properti
larg
number
chemic
modif
aim
replac
compound
anilin
motif
retain
ppias
inhibitori
activ
made
includ
replac
amino
group
follow
halogen
f
cl
br
hydroxyl
methoxi
ester
acetamid
replac
pyridin
aminopyridin
heterocycl
sometim
contain
amin
function
fuse
nonfus
bicycl
substitut
methoxi
alkyl
group
list
structur
compound
test
ppias
inhibitori
activ
shown
supplementari
tabl
among
compound
anilin
motif
replac
retain
ppias
inhibitori
potenc
parent
compound
ic
mm
cypa
cypb
cypd
respect
tabl
addit
replac
compound
anilin
motif
led
gener
compound
although
less
activ
parent
compound
retain
signific
ppias
inhibitori
activ
ic
mm
cypa
cypb
cypd
respect
tabl
hand
macrocycl
attempt
stabil
bioactiv
conform
compound
howev
macrocycl
compound
supplementari
tabl
inact
cyclophilin
ppias
activ
contrast
addit
phenyl
ring
urea
carbonyl
compound
stabil
bioactiv
conform
pp
interact
two
phenyl
moieti
lead
least
threefold
gain
antippias
activ
ultim
compound
potent
cyclophilin
inhibitor
gener
ic
mm
cypa
cypb
cypd
respect
tabl
broadspectrum
antivir
activ
cell
harbour
hcv
genotyp
replicon
treat
increas
concentr
compound
shown
tabl
inhibit
hcv
replicon
replic
dosedepend
manner
ec
rang
mm
repres
inhibitori
curv
shown
compound
supplementari
fig
ec
csa
compound
potent
inhibitor
rang
mm
versu
mm
respect
higher
ec
csa
deriv
alisporivir
mm
tabl
compound
cytotox
effect
concentr
antivir
activ
compound
also
assess
hiviiib
replic
cell
test
compound
inhibit
hiv
replic
better
csa
ec
rang
mm
compound
cytotox
effect
concentr
tabl
final
antivir
activ
compound
assess
human
coronaviru
cell
seven
test
compound
inhibit
replic
ec
rang
mm
without
associ
cytotox
tabl
effect
protein
substitut
antihcv
activ
substitut
domain
ii
protein
report
associ
slightli
reduc
hcv
suscept
antivir
action
csa
nonimmunosuppress
deriv
correspond
nucleotid
substitut
introduc
genotyp
subgenom
replicon
mean
sitedirect
mutagenesi
antivir
activ
compound
measur
mutat
replicon
comparison
wildtyp
replicon
result
shown
tabl
indic
substitut
slightli
reduc
suscept
compound
chang
ec
order
chang
csa
alisporivir
suscept
induc
lack
calcineurin
inhibit
properti
addit
anticyclophilin
activ
csa
display
potent
immunosuppress
properti
format
stabl
ternari
complex
stoichiometri
calcineurin
cypa
csa
result
inhibit
calcineurin
phosphatas
activ
although
new
famili
inhibitor
unrel
csa
preincub
studi
perform
binari
complex
form
cypa
compound
determin
whether
complex
inhibit
calcineurin
phosphatas
activ
shown
supplementari
fig
dosedepend
decreas
calcineurin
activ
observ
presenc
increas
concentr
cypacsa
complex
use
posit
control
inhibit
contrast
inhibit
observ
presenc
binari
complex
cypa
compound
addit
csa
potent
inhibit
interleukin
il
product
stimul
immort
lymphocyt
jurkat
cell
ec
mm
wherea
compound
effect
product
ec
mm
vitro
metabol
compound
assess
vitro
metabol
compound
synthes
result
summar
supplementari
tabl
measur
octanolwat
partit
logd
valu
compound
respect
compound
solubl
ph
ph
degrad
incub
pb
h
slightli
degrad
incub
hcl
n
ph
h
compound
compound
remain
h
permeabl
high
compound
wherea
efflux
neglig
compound
low
compound
monolay
cell
suggest
high
absorpt
potenti
famili
bind
human
plasma
protein
compound
respect
high
recoveri
indic
satisfactori
plasma
stabil
therefor
compound
predict
display
low
shift
biolog
potenc
presenc
human
plasma
compar
cell
cultur
medium
metabol
stabil
studi
use
human
hepat
microsom
fraction
presenc
nadph
support
oxid
metabol
compound
metabol
microsom
fraction
vitro
halfliv
min
respect
yield
moder
predict
clearanc
neither
compound
compound
metabol
compound
metabol
highest
rate
compound
compound
metabol
rel
contribut
individu
enzym
metabol
compound
could
determin
experi
data
suggest
compound
predominantli
metabol
enzym
neither
compound
compound
significantli
inhibit
compound
moder
inhibitor
potent
inhibitor
suggest
possibl
drugdrug
interact
inhibit
enzym
studi
use
fbdd
creat
new
famili
nonpeptid
smallmolecul
cyclophilin
inhibitor
unrel
csa
sfa
potent
ppias
inhibitori
activ
potent
antivir
effect
hcv
hiv
coronavirus
vitro
fbdd
emerg
effect
approach
drug
discoveri
nearli
year
ago
fbdd
inde
gener
number
new
drug
class
includ
reach
medic
market
fbdd
base
screen
lowmolecularweight
molecul
minim
chemic
complex
bind
subpocket
within
target
site
fragment
typic
bind
low
affin
mm
mm
rang
repres
suitabl
start
point
structur
guid
hittolead
optim
fragmentbas
approach
offer
better
coverag
chemic
divers
space
highthroughput
screen
offer
advantag
structurebas
chemic
optim
cyclophilin
ppias
catalyt
groov
form
mixtur
hydrophob
aromat
polar
residu
highli
conserv
across
differ
cyclophilin
notabl
sidechain
guanidin
group
essenti
hydrogen
bond
prolyl
nitrogen
substrat
promot
isomer
weaken
doublebond
properti
peptid
bond
target
residu
thu
crucial
achiev
potent
inhibit
ppias
activ
csa
nonimmunosuppress
cyclic
analogu
sfa
larg
macrocycl
compound
molecular
weight
g
mol
bind
cyclophilin
catalyt
site
potent
inhibit
ppias
activ
howev
shortcom
famili
compound
clinic
practic
emphas
need
develop
smallmolecul
cyclophilin
inhibitor
cyclophilin
catalyt
site
buri
pocket
design
small
ligand
molecular
weight
g
mol
nevertheless
challeng
deeper
pocket
gatekeep
pocket
identifi
close
vicin
ppias
catalyt
site
pocket
could
contribut
substrat
bind
specif
gatekeep
residu
locat
surfac
restrict
substrat
access
thu
gatekeep
pocket
appear
interest
target
close
catalyt
site
suitabl
fragmentbas
approach
target
site
combin
link
strategi
common
approach
chemic
optim
fragment
grow
strategi
permit
multistep
optim
ligand
effici
size
within
bind
site
altern
link
strategi
constrain
size
origin
fragment
linker
therefor
result
rapid
buildup
atom
singl
step
furthermor
conform
strain
flexibl
mean
energi
price
often
need
paid
achiev
optim
link
fragment
spite
challeng
target
two
differ
subpocket
decid
use
approach
link
two
fragment
bind
catalyt
gatekeep
pocket
respect
substanti
improv
stabil
bind
affin
result
molecul
mean
structurebas
drug
design
select
linker
consist
urea
moieti
mimick
key
interact
csa
sfa
cyclophilin
without
alter
bind
mode
two
fragment
alon
result
thu
show
link
fragment
bind
adjac
site
power
approach
complex
target
optim
linker
found
compound
display
potent
vitro
activ
cypa
cypb
cypd
ppias
activ
unlik
csa
new
famili
cyclophilin
inhibitor
effect
calcineurin
phosphatas
activ
respons
csa
immunosuppress
properti
addit
earli
pharmacolog
studi
vitro
cellular
toxic
experi
suggest
compound
famili
druggabl
presenc
anilin
motif
may
associ
toxic
anim
model
man
sever
round
chemic
optim
perform
remov
anilin
motif
led
gener
compound
anilin
motif
retain
antippias
antivir
activ
risk
relat
anilin
motif
must
balanc
sever
target
diseas
costbenefit
ratio
requir
durat
administr
instanc
would
consid
major
safeti
issu
treat
benign
diseas
requir
longterm
administr
would
unimport
case
shortterm
treatment
sever
eventu
lifethreaten
acut
infect
thu
lead
compound
without
anilin
motif
move
forward
throughout
preclin
develop
compound
describ
repres
first
nonpeptid
smallmolecul
cyclophilin
inhibitor
famili
broadspectrum
antivir
properti
describ
thu
far
base
previou
work
group
chines
author
report
seri
thioureabas
inhibitor
target
capsid
human
cypa
inhibit
assembl
uncoat
viral
capsid
howev
low
cypabind
affin
compound
strongli
contradict
claim
ppias
inhibitori
activ
report
effect
hiv
could
exclus
relat
capsid
ligand
properti
compound
work
anoth
seri
smallmolecul
cypa
inhibitor
report
result
de
novo
drug
design
synthes
two
best
compound
purchas
one
tocri
bioscienc
test
abil
inhibit
ppias
activ
hcv
coronaviru
replic
vitro
shown
supplementari
tabl
none
compound
exhibit
biolog
activ
model
furthermor
could
obtain
crystallograph
structur
compound
complex
cyclophilin
anoth
articl
close
relat
compound
test
enteroviru
ref
vitro
resist
select
experi
identifi
one
amino
acid
substitut
select
sever
passag
increas
concentr
compound
substitut
confer
modest
fivefold
reduct
suscept
resist
csa
challeng
hypothesi
common
mechan
inhibit
two
molecul
altogeth
result
cast
doubt
realiti
anticyclophilin
properti
class
molecul
famili
compound
report
inhibit
cyclophilin
activ
vitro
need
extern
valid
potenti
broadspectrum
antivir
compound
evalu
result
emphas
difficulti
develop
efficaci
smallmolecul
cyclophilin
inhibitor
unrel
csa
sfa
underlin
origin
import
work
cyclophilin
repres
interest
target
broadspectrum
antivir
drug
inde
sever
cyclophilin
princip
cypa
convincingli
shown
play
pivot
role
life
cycl
number
viral
famili
result
show
inhibit
hcv
hiv
coronaviru
compound
relat
compound
togeth
preliminari
data
suggest
hepat
b
viru
replic
inhibit
support
futur
develop
new
famili
cyclophilin
inhibitor
broadspectrum
antivir
compound
high
barrier
resist
high
barrier
resist
demonstr
csa
deriv
hcv
infect
result
fact
cyclophilin
inhibitor
directli
target
viral
function
instead
target
host
protein
involv
key
step
viral
life
cycl
thu
likelihood
select
virus
resist
action
drug
low
virus
select
would
unlik
yield
high
level
resist
alreadi
shown
confirm
demonstr
amino
acid
substitut
hcv
protein
known
modestli
reduc
csaand
csaderiv
inhibitor
suscept
hcv
also
modestli
affect
hcv
suscept
new
compound
experi
show
compound
inhibit
mptp
open
result
cypd
inhibit
panel
ahmedbelkacem
et
al
manuscript
prepar
suggest
new
famili
cyclophilin
inhibitor
also
potenti
medic
util
number
patholog
condit
mptp
open
shown
involv
protect
cardiac
ischaemiareperfus
injuri
protect
hepat
ischaemiareperfus
injuri
context
liver
transplant
neurocellular
protect
context
alzheim
diseas
conclus
use
fbdd
combin
link
strategi
structurebas
compound
optim
gener
new
famili
nonpeptid
smallmolecul
cyclophilin
inhibitor
unrel
csa
sfa
potent
ppias
inhibitori
activ
antivir
effect
hcv
hiv
coronavirus
vitro
druggabl
properti
famili
compound
potenti
use
highbarriertoresist
treatment
viral
infect
use
cyclophilin
life
cycl
well
variou
medic
applic
cypdmptp
openingrel
cellular
protect
express
purif
cypd
mutant
human
cypd
express
escherichia
coli
strain
bacteria
grown
luria
broth
medium
optic
densiti
od
nm
induc
h
isopropylbdthiogalactopyranosid
cell
lyse
sonic
buffer
compos
mm
tri
ph
mm
edta
mm
bmercaptoethanol
cell
lysat
clarifi
centrifug
g
min
supernat
load
qsepharos
ssepharos
column
seri
equilibr
buffer
ssepharos
column
wash
equilibrium
buffer
bound
protein
elut
linear
gradient
nacl
combin
peak
fraction
load
column
equilibr
mm
tri
ph
mm
nacl
mm
edta
mm
dithiothreitol
dtt
twostep
purif
protocol
suffici
yield
pure
protein
n
label
nmr
experi
obtain
grow
bacteria
medium
nlabel
ammonium
chlorid
sole
nitrogen
sourc
label
cypd
purifi
describ
express
purif
cypa
cypb
cypa
cypb
protein
carri
hexahistidin
tag
histag
carboxi
terminu
express
e
coli
purifi
briefli
cultur
cell
grown
h
cultur
reach
od
nm
induc
mm
isopropylbdthiogalactopyranosid
h
cypa
overnight
cypb
cell
pellet
resuspend
lysi
buffer
mm
nah
po
ph
mm
nacl
mm
bmercaptoethanol
mg
ml
lysozym
u
ml
desoxyribonucleas
complet
proteas
inhibitor
tablet
roch
diagnost
corpor
indianapoli
indiana
sonic
cell
lysat
clarifi
centrifug
g
min
chromatograph
ninta
column
wash
buffer
contain
mm
nah
po
ph
mm
nacl
mm
imidazol
mm
bmercaptoethanol
glycerol
bound
protein
elut
ml
fraction
buffer
compos
mm
nah
po
ph
mm
nacl
mm
imidazol
mm
bmercaptoethanol
glycerol
monitor
bradford
colorimetr
assay
puriti
cyclophilin
determin
coomassiestain
sdspage
analysi
fraction
enrich
cyclophilin
puriti
pool
dialys
buffer
contain
mm
nah
po
ph
mm
nacl
mm
dtt
mm
edta
glycerol
ppias
enzym
assay
cyclophilin
ppias
activ
measur
use
standard
chymotrypsincoupl
assay
assay
buffer
mm
hepe
mm
nacl
ph
cyclophilin
nm
stock
solut
precool
ml
mg
ml
chymotrypsin
mm
hcl
ad
reaction
initi
ad
ml
mm
peptid
substrat
sucalaalacisprophepna
licltf
solut
rapid
invers
delay
onset
mix
absorb
pnitroanilin
follow
nm
reaction
complet
min
final
concentr
licl
assay
mm
tfe
present
concentr
vv
absorb
read
collect
everi
spectrophotomet
inhibit
assess
ml
test
compound
dimethyl
sulfoxid
dmso
ad
cyclophilin
solut
assay
buffer
csa
use
posit
control
measur
percentag
inhibit
cyclophilin
ppias
activ
calcul
slope
valu
obtain
repres
least
two
independ
measur
fragment
librari
design
dock
fragment
purchas
acro
organ
geel
belgium
sigmaaldrich
saint
loui
missouri
maybridg
tintagel
uk
chembridg
san
diego
california
filter
appli
onedimension
filter
molecular
weight
g
mol
base
rule
three
virtual
librari
dock
use
programm
interfac
base
dock
programm
flexx
xray
coordin
cypd
pdbid
use
dock
fragment
site
dock
defin
cover
entir
activ
site
includ
catalyt
site
gatekeep
pocket
water
molecul
includ
bind
site
dock
top
pose
dock
manual
inspect
compound
synthesi
chemic
reagent
obtain
aldrich
chemic
saint
loui
missouri
acro
organ
abcr
gmbh
karlsruh
germani
acb
block
toronto
canada
chembridg
use
without
purif
compound
synthesi
describ
supplementari
method
associ
comment
nmr
experi
nmr
sampl
use
screen
contain
mm
nlabel
protein
buffer
consist
mm
kh
po
ph
nhsqc
experi
record
k
presenc
bruker
avanc
mhz
spectromet
equip
cryoprob
typic
acquisit
time
min
per
experi
mixtur
ten
fragment
cocktail
individu
concentr
mm
screen
cocktail
solubl
water
dmsod
use
wherea
dmsod
use
solubil
cocktail
insolubl
water
attribut
nhsqc
spectrum
cypd
deposit
biolog
magnet
reson
bank
bmrb
entri
use
reattribut
nhsqc
spectrum
protein
presenc
dmsod
fragment
bind
detect
compar
nhsqc
spectra
presenc
absenc
fragment
mixtur
fragment
cocktail
caus
signific
perturb
nhsqc
spectrum
residu
activ
site
one
nhsqc
spectrum
ncypd
record
presenc
individu
fragment
nmr
data
process
use
bruker
softwar
xwinnmr
version
analys
comparison
made
inhous
softwar
cindi
fragment
screen
nmr
experi
compound
record
inova
agil
mhz
spectromet
equip
triplereson
n
probe
nhsqc
spectra
record
mm
protein
mm
compound
mm
compound
reson
assign
ligand
bind
check
use
threedimension
nuclear
verhaus
enhanc
nhsqc
spectra
ms
mix
time
h
c
nmr
spectra
compound
shown
supplementari
fig
crystal
structur
determin
ligandcypd
crystal
apo
cypd
suitabl
ligand
soak
obtain
procedur
describ
schlatter
et
al
briefli
cypd
buffer
exchang
mm
kh
po
ph
mm
nacl
mm
dtt
mm
edta
concentr
mg
ml
apo
cypd
crystal
grown
use
hang
drop
vapour
diffus
method
drop
form
mix
ml
protein
equal
volum
mother
liquor
contain
wv
peg
equilibr
ml
solut
crystal
form
one
night
xray
screen
process
requir
larg
amount
reproduc
crystal
avail
soak
thu
crystal
procedur
optim
seed
method
use
seed
bead
protocol
hampton
research
aliso
viejo
california
fragment
soak
satur
solut
immers
oil
centistok
sigmaaldrich
dmso
stock
solut
made
crystal
ad
satur
immers
oil
min
day
ml
dmso
stock
solut
ad
grow
drop
min
h
flash
freez
data
collect
crystal
soak
dmso
stock
solut
cryoprotect
data
collect
brief
immers
oil
xray
diffract
data
collect
inhous
xray
gener
rigaku
tokyo
japan
imag
plate
detector
marresearch
norderstedt
germani
european
synchrotron
radiat
facil
grenobl
franc
beamlin
data
integr
process
use
mosflm
scala
suit
crystal
belong
space
group
b
c
one
monom
asymmetr
unit
structur
solv
molecular
replac
use
pdb
entri
search
model
bound
ligand
manual
identifi
fit
f
f
c
electron
densiti
use
coot
structur
refin
round
rebuild
coot
refin
use
refmac
suit
data
collect
refin
statist
crystal
structur
present
supplementari
tabl
crystal
structur
determin
ligandcypa
crystal
apo
cypa
suitabl
ligand
soak
obtain
mean
hang
drop
vapour
diffus
mix
ml
cypa
mg
ml
mm
tri
ph
mm
nacl
ml
hepe
mm
ph
peg
wv
ethanol
equilibr
ml
solut
crystal
form
one
night
ml
dmso
stock
solut
compound
ad
grow
drop
min
flash
freez
data
collect
xray
diffract
data
collect
inhous
xray
gener
imag
plate
detector
data
integr
process
use
mosflm
scala
suit
crystal
belong
space
group
b
c
one
monom
asymmetr
unit
structur
solv
molecular
replac
use
pdb
entri
search
model
bound
ligand
manual
identifi
fit
f
f
c
electron
densiti
use
coot
structur
refin
round
rebuild
coot
refin
use
refmac
suit
data
collect
refin
statist
crystal
structur
present
supplementari
tabl
isotherm
titrat
calorimetri
protein
dialys
buffer
contain
mm
hepe
ph
mm
nacl
twenti
mm
protein
load
microc
vpitc
malvern
orsay
franc
isotherm
titrat
calorimet
cell
ml
cell
volum
ml
titrat
syring
ml
volum
fill
mm
ligand
solut
buffer
titrat
carri
use
inject
ml
inject
min
interv
stir
speed
rpm
titrat
carri
constant
temperatur
data
fit
singl
site
bind
model
use
origin
softwar
assess
antihcv
activ
hcv
genotyp
bicistron
replicon
transfect
cell
grown
dmem
medium
glutamax
ii
invitrogen
carlsbad
california
supplement
fetal
bovin
serum
iu
ml
penicillin
mg
ml
streptomycin
mg
ml
fungizon
mg
ml
geneticin
hcv
repliconharbour
cell
seed
low
densiti
cell
per
well
plate
cell
treat
increas
concentr
test
compound
dmem
contain
fetal
bovin
serum
dmso
without
cultur
day
total
rna
extract
use
rneasi
kit
qiagen
hilden
germani
hcv
rna
level
measur
mean
quantit
realtim
pcr
assay
use
taqman
technolog
hcvspecif
primer
sens
cgcccaaaccagaatacg
antisens
probe
abi
devic
appli
biosystem
foster
citi
california
hcv
rna
level
measur
mean
nanodrop
spectrophotomet
nanodrop
technolog
wilmington
delawar
result
normal
gapdh
gene
data
point
repres
averag
least
three
replic
cell
cultur
hcv
rna
level
reduct
treatment
assess
compar
level
hcv
rna
compoundtr
cell
control
cell
treat
dmso
assess
antihiv
activ
compound
dilut
dmso
ml
ad
ml
cell
growth
medium
rpmi
fetal
bovin
serum
penicillinstreptomycin
lglutamin
hepe
well
assay
plate
concentr
quadrupl
onemillilitr
aliquot
cell
preinfect
h
respect
ml
either
cell
growth
medium
fresh
dilut
hiviiib
concentr
abi
stock
multipl
infect
infect
uninfect
cell
dilut
cell
growth
medium
ml
suspens
cell
ad
well
assay
plate
respect
assay
plate
incub
incub
day
incub
ml
twofold
concentr
celltiterglo
reagent
promega
bioscienc
madison
wisconsin
ad
well
assay
plate
cell
lysi
carri
incub
room
temperatur
min
chemiluminesc
read
use
envis
multimod
plate
reader
perkinelm
waltham
massachusett
data
convert
percentag
untreat
control
nonlinear
regress
perform
calcul
ec
valu
compound
cytotox
assess
protocol
ident
except
uninfect
cell
use
assess
antihuman
coronaviru
activ
cell
rdbiotech
franc
cultur
dmem
contain
fc
u
ml
penicillin
mg
ml
streptomycin
mg
ml
amphotericin
b
fungizon
life
technolog
carlsbad
california
twelv
hour
infect
cell
seed
densiti
cell
per
well
plate
cell
infect
human
coronaviru
multipl
infect
dmem
contain
fc
u
ml
penicillin
mg
ml
streptomycin
mg
ml
amphotericin
b
h
presenc
increas
concentr
inhibitor
viral
cytopath
effect
quantifi
cytotoxglo
cytotox
assay
promega
madison
wisconsin
virusinduc
cytotox
calcul
rel
light
unit
signal
infect
treat
cell
minu
rel
light
unit
signal
noninfect
treat
cell
calcineurin
phosphatas
assay
inhibit
calcineurin
phosphatas
activ
measur
measur
dephosphoryl
pnitrophenyl
phosphat
r
system
minneapoli
usa
accord
manufactur
instruct
briefli
csa
compound
incub
molar
ratio
recombin
cypa
room
temperatur
min
presenc
nm
calcineurin
nm
calmodulin
pnitrophenyl
phosphat
addit
reaction
run
min
reaction
termin
addit
biomol
green
reagent
od
measur
nm
result
mean
three
independ
experi
perform
duplic
present
percentag
calcineurin
activ
rel
inhibitorfre
control
inhibit
product
jurkat
cell
jurkat
cell
cell
per
well
pretreat
h
either
compound
concentr
rang
mm
csa
concentr
rang
mm
duplic
evalu
includ
test
concentr
end
pretreat
period
cell
induc
mixtur
phorbol
myrist
acet
ionomycin
ng
ml
mm
respect
h
incub
sampl
supernat
collect
measur
product
use
commerci
kit
quantikin
elisa
r
system
logd
determin
octanolwat
partit
logd
valu
compound
determin
retent
time
reversephas
hplc
ph
diod
array
ultravioletvis
detect
logd
valu
obtain
interpol
within
standard
curv
rang
logd
gener
seven
standard
logd
valu
previous
determin
use
shakeflask
method
solubl
chemic
stabil
kinet
solubl
determin
dilut
dmso
stock
compound
test
media
solut
pb
ph
n
hcl
ph
final
concentr
mm
total
dmso
concentr
vv
solut
incub
room
temperatur
shake
h
centrifug
recov
supernat
assay
hplc
diod
array
ultravioletvis
detect
solubl
valu
calcul
compar
amount
chromatograph
peak
area
compound
detect
defin
test
solut
unextract
standard
rel
chemic
stabil
compound
h
incub
pb
also
determin
solubl
chemic
stabil
qualitycontrol
compound
amprenavir
determin
parallel
cell
permeabl
permeabl
efflux
potenti
determin
use
confluent
day
monolay
cell
grown
transwel
filter
compound
ad
donor
well
target
concentr
mm
rate
appear
receiv
well
contain
bsa
maintain
sink
condit
determin
liquid
chromatographi
coupl
tandem
mass
spectrometri
lcmsm
qualiti
control
includ
transepitheli
electr
resist
lucif
yellow
exclus
low
atenolol
high
propranolol
permeabl
control
abil
demonstr
polar
efflux
digoxin
protein
bind
extent
bind
pool
human
plasma
cell
cultur
medium
contain
fetal
bovin
serum
determin
equilibrium
dialysi
isoton
phosphat
buffer
equilibrium
dialysi
conduct
initi
concentr
compound
mm
nonbuff
matrix
h
dialysi
time
use
equilibr
follow
dialysi
plasma
sampl
drain
preweigh
polypropylen
tube
contain
buffer
buffer
sampl
drain
preweigh
tube
contain
blank
plasma
postdialysi
plasma
buffer
weight
measur
record
concentr
recoveri
calcul
precipit
centrifug
lcmsm
assay
use
analysi
proteinphosph
buffermix
matric
rel
bind
human
plasma
cell
cultur
medium
determin
similar
manner
except
two
matric
dialys
directli
compound
spike
matric
equilibr
plasma
sampl
dilut
blank
cell
cultur
medium
cell
cultur
medium
dilut
blank
plasma
stabil
hepat
microsom
fraction
compound
mm
incub
duplic
h
presenc
human
hepat
microsom
fraction
mg
protein
ml
final
addit
cofactor
solut
nadph
gener
system
initi
reaction
aliquot
remov
min
start
concentr
compound
sampl
determin
use
specif
lcmsm
assay
halflif
disappear
determin
fit
concentrationtim
data
monophas
exponenti
model
control
compound
verapamil
run
parallel
test
enzymat
integr
microsom
fraction
metabol
recombin
human
cytochrom
five
micromol
compound
incub
individu
bacteri
express
recombin
human
cytochrom
coexpress
human
nadph
cytochrom
reductas
reduct
substrat
concentr
monitor
min
use
specif
lcmsm
assay
vitro
halflif
calcul
manner
describ
hepat
microsom
stabil
enzymeselect
posit
control
substrat
test
parallel
cytochrom
enzym
inhibit
assay
mm
compound
incub
human
hepat
microsom
fraction
nadph
presenc
individu
probe
substrat
assay
design
condit
linear
respect
time
protein
concentr
substrat
present
concentr
equal
lower
respect
km
valu
enzym
select
product
determin
fluorometri
ethoxyresorufin
odeethylas
specif
lcmsm
assay
rel
enzym
activ
determin
comparison
assay
dmso
vehicl
instead
inhibitor
ic
valu
calcul
nonlinear
curv
fit
use
sigmoid
model
posit
control
inhibitor
enzym
test
parallel
